ANAPTYSBIO, INC Amended Passive Investment Disclosure
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership in AnaptysBio, Inc. common stock has fallen below 5% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership in AnaptysBio, Inc. common stock has fallen below 5% of the class. Morgan Stanley reports beneficial ownership of 1,006,063 shares, representing 3.6% of AnaptysBio’s common stock.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 879,351 shares, or 3.2% of the class, and also notes it is no longer a beneficial owner of more than five percent. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of AnaptysBio.
AI-generated analysis. How Rhea-AI works. Not financial advice.